Detalhe da pesquisa
1.
Current and upcoming treatment approaches to common subtypes of PTCL (PTCL NOS, ALCL, TFHs).
Blood
; 2024 Feb 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38306597
2.
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.
Haematologica
; 109(4): 1149-1162, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646671
3.
Emapalumab as salvage therapy for adults with malignancy-associated hemophagocytic lymphohistiocytosis.
Haematologica
; 2024 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38752279
4.
Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphoma.
Br J Haematol
; 202(3): 525-529, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37217196
5.
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results.
Blood
; 138(6): 427-438, 2021 08 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33827139
6.
A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas.
Blood
; 138(26): 2828-2837, 2021 12 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-34653242
7.
Current Treatment of Peripheral T-cell Lymphoma.
Oncology (Williston Park)
; 36(5): 293-305, 2022 05 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35576176
8.
Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma.
Blood
; 133(20): 2121-2129, 2019 05 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-30770396
9.
Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts.
Am J Hematol
; 96(10): 1211-1222, 2021 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34251048
10.
Nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma.
Blood
; 141(22): 2780-2783, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36898084
11.
Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.
Blood
; 131(11): 1183-1194, 2018 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29229594
12.
Outcomes and prognostic factors in African American and black patients with mycosis fungoides/Sézary syndrome: Retrospective analysis of 157 patients from a referral cancer center.
J Am Acad Dermatol
; 83(2): 430-439, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31499157
13.
Gemcitabine plus pembrolizumab after checkpoint blockade failure as a strategy in multiply relapsed Hodgkin lymphoma.
Br J Haematol
; 204(2): e17-e20, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37905372
14.
Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma.
Blood
; 130(20): 2196-2203, 2017 11 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-28874350
15.
BEAM versus pharmacokinetics-directed BuCyVP16 conditioning for patients with peripheral T-cell lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation.
Am J Hematol
; 99(6): 1180-1183, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38526002
16.
Angioimmunoblastic T-Cell Lymphoma.
Cancer Treat Res
; 176: 99-126, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30596215
17.
Cutaneous T-cell lymphoma and dupilumab use: A retrospective matched cohort study of clinical characteristics and treatment outcomes.
J Eur Acad Dermatol Venereol
; 2024 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-38818876
18.
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Lancet Oncol
; 19(9): 1192-1204, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30100375
19.
PD-1 blockade for untreated Hodgkin lymphoma.
Blood
; 137(10): 1271-1272, 2021 03 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33704392
20.
Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma.
Blood
; 128(11): 1458-64, 2016 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27458003